MBMarie-Anne Burckhardt

Marie-Anne Burckhardt

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Marie-Anne Burckhardt has a total of 153 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Towards Electronic Health Records-Based Paediatric Growth References: Results from the SwissPedGrowth Project

    by Lorenz M. Leuenberger, Yara Shoman, Franco Romero, Mari Sasaki, Xeni Deligianni, Nicole Goebel, Rebeca Mozun, Julia A. Bielicki, Marie-Anne Burckhardt, Christoph Saner, et al.

    BACKGROUND: We used anthropometric data from electronic health records (EHRs) of Swiss children’s hospitals to evaluate growth references and estimate centile curves. METHODS: We received EHRs extracted from seven Swiss children’s hospitals and analysed two samples: all children with a height, weight, body mass index (BMI), or head circumference recording, and a subsample restricted to children without diseases potentially affecting growth, weighted to represent the general population. We calculated mean z-scores based on the World Health Organization growth references adopted for Switzerland in 2011 (CH-WHO 2011) and current Swiss growth references (Swiss 2026). We estimated sex-specific centile curves in the subsample using generalised additive models for location, scale, and shape. RESULTS: We included 213,868 children with height, 448,002 with weight, 209,244 with BMI, and 67,397 with head circumference recordings. Mean z-scores in the ‘all children’ sample were (CH- WHO 2011; Swiss 2026): height (0.10; -0.19), weight (0.16; -0.09), BMI (0.04; -0.07), head circumference (-0.28, -0.28); and in the subsample: height (0.34; 0.00), weight (0.27; 0.01), BMI (0.18; 0.05), and head circumference (0.04; 0.01). The 50 th height, weight, BMI, and head circumference centiles of girls and boys in the subsample closely followed those of Swiss 2026, with slightly wider 3 rd and 97 th centiles in infancy and adolescence. CONCLUSION: Height, weight, BMI, and head circumference centiles aligned well with the Swiss 2026 growth references in Switzerland, demonstrating that hospital EHRs could contribute to future growth references.

  • Open Access

    Availability and Quality of Anthropometric Data in Swiss Children’s Hospitals: The SwissPedGrowth Project

    by Lorenz M. Leuenberger, Yara Shoman, Franco Romero, Xeni Deligianni, Anna Hartung, Rebeca Mozun, Nicole Goebel, Julia A. Bielicki, Marie-Anne Burkhardt, Philipp Latzin, et al.

    OBJECTIVE: Anthropometric data are critical in paediatric care, routinely assessed during clinical visits, and available in electronic health records (EHRs). We describe the feasibility of extracting anthropometric data from heterogeneous EHR systems of Swiss children’s hospitals, evaluate their availability and quality, and assess the cohort’s representativeness of the general population. METHODS: In this multicentre study (SwissPedGrowth), we retrospectively collected EHRs from patients <20 years who visited hospitals in Basel, Bern, Geneva, Lausanne, Luzern, St. Gallen, or Zurich between 2017–2023. Sociodemographic, administrative, and clinical information from EHRs were provided in a standardized way by a paediatric national data stream (SwissPedHealth), including the Swiss Neighbourhood Index of Socioeconomic Position (Swiss-SEP). We counted anthropometric recordings per visit to describe availability and used a self-developed and an existing (growthcleanr) algorithm to investigate data quality. To assess representativeness, we compared sociodemographic characteristics between SwissPedGrowth and the general paediatric population in Switzerland, computed standardized differences (effect size: 0.2 small, 0.5 medium, 0.8 large), and weighted the study population to reduce differences. RESULTS: We included 477,531 patients and 2,171,633 hospital visits—54% boys, 71% Swiss, mean Swiss-SEP 65 (SD: 11), and median age at visit 6.3 [IQR: 2.3, 11.8] years. Height recordings were available for 20% of the visits, weights for 43%, and head circumferences for 5%, with better availability for inpatient stays than outpatient or emergency visits. Combining the self-developed and existing algorithm, 4% of heights and 3% of weights were flagged as outliers and 29% of heights and 31% of weights as carried forward from previous visits or same day duplicates. Sociodemographic differences between SwissPedGrowth and the general population were small or small-to-medium and disappeared after weighting. CONCLUSION: SwissPedGrowth demonstrates feasibility of extracting high-quality anthropometric data for paediatric growth research, but challenges regarding completeness and harmonization of EHR data across Swiss hospitals remain.


  • Hypercholesterolemia and Lipid-Lowering Therapy in Children and Adolescents With Type 1 Diabetes: Do We Implement Current Guidelines?

    by Jantje Weiskorn, Marianne Becker, Clemens Kamrath, Johanna Hammersen, Susanne Bechtold-Dalla Pozza, Elke Müller-Roßberg, Martin Holder, Marie-Anne Burckhardt, Reinhard Walter Holl

    OBJECTIVE: We investigated the prevalence of elevated LDL cholesterol in youth with type 1 diabetes (T1D), contributing factors, the frequency of lipid-lowering medication (LLM), and the achievement of target values. RESEARCH DESIGN AND METHODS: A cross-sectional analysis based on data from the Diabetes-Patienten-Verlaufsdokumentation registry (Diabetes Prospective Follow-up Registry) from 2013 to 2023. Inclusion criteria were T1D, age 2.6, >3.4, and >4.1 mmol/L were defined. Application of national and international treatment guidelines was examined. Descriptive analyses and linear and logistic regression models were implemented using SAS 9.4. RESULTS: The study included 55,028 participants. Of these, 9.7% and 2.3% had LDL >3.4 mmol/L and >4.1 mmol/L, respectively. The parameters HbA1c (β = 1,142.7; P = 0.001), female sex (β = 861.5; P < 0.001), and BMI >70th percentile (β = 520.1; P < 0.001) had the strongest effect on LDL levels. Only 7.3% of the cohort with elevated LDL levels received LLM. The majority (92.7%) with LDL >3.4 mmol/L and 87.0% with LDL >4.1 mmol/L were not treated. Estimated odds ratios (95% CI) for the use of LLM were 19.13 (15.4–23.7) for LDL >4.1 mmol/L; 3.1 (1.82–5.41) for ages 12–18 years; 2.31 (1.9–2.1) for diabetes duration of 5–10 years; 1.8 (1.5–2.1) for BMI >70th percentile; 1.3 (1.0–1.6) for HbA1c >9%; and 1.18 (1.0–1.4) for female sex. However, only 15.7% of the treated patients (n = 707) reached the LDL target of 3.4 mmol/L. CONCLUSIONS: We found a high prevalence of LDL hypercholesterolemia. The use of LLM was low, despite treatment indication, and treatment targets were mostly not achieved either due to underdosing or nonadherence to LLM. These findings confirm that dyslipidemia remains an underestimated cardiovascular risk factor in pediatric diabetology.

  • Open Access

    Pubertal Assessment and Growth in Patients With Hemoglobinopathies: A Longitudinal Multicenter Study on the Association With Ferritin Levels

    by J. Dülberg, C. Sanchez, M.‐A. Burckhardt, L. Alacán Friedrich, V. Salow, A. Radauer‐Plank, A. Borgmann‐Staudt, H. Cario, M. Diepold, B. Drexler, et al.

    Objectives: Although Advancements in the Treatment of Hemoglobinopathies have Considerably Increased Life Expectancy, Hormonal and Pubertal Development Have Been Continuously Affected by Complications From Transfusion‐Related Iron Overload and Cytotoxic Therapies. This Study Investigated the Association Between Serum Ferritin Levels and Pubertal Progression in Patients With Thalassemia and Sickle Cell Disease ( SCD ). Methods: Data Collected From 10 Hospitals in Austria, Germany, and Switzerland From 2012 to 2020 Were Retrospectively Analyzed. We Enrolled 140 Individuals (Median Age: 16.5 Years) With Thalassemia or SCD. Results: Overall, Delayed Puberty Was Observed in 14.7% (6.7% Females; 21.1% Males) and 13.2% of Patients With Thalassemia and SCD (6.9% Females; 20.8% Males), respectively. Gonadal Insufficiency Was Found in 13.3% and 8.6% of Females With Thalassemia and SCD , Respectively. Abnormal Growth Trajectories Were Observed in 32.5% (28.5% Females; 36.8% Males) and 18.7% of Patients With Thalassemia and SCD (13.3% Females; 23.5% Males), respectively. A Statistically Significant Association Was Found Between Elevated Ferritin Levels and Growth Delays in Patients With Thalassemia. Notably, Tanner Staging Data Were Missing in 80.7% of the Medical Records. Conclusions: Our Results Indicated the Need for Comprehensive Pubertal Screening and Underscored the Importance of Robust Endocrine Follow‐Up Care in Individuals With Hemoglobinopathies.

  • Open Access

    Swiss Diabetes and Technology recommendations

    by Giacomo Gastaldi, Lia Bally, Marie-Anne Burckhardt, Elena Gamarra, Michael Hauschild, Daniel Konrad, Roger Lehmann, Camillo Piazza, Marie-Alice Savet, Valérie Schwitzgebel, et al.

    Technological advancements have significantly reshaped diabetes care. Diabetes and technology now encompass the hardware, devices and software required to treat diabetes mellitus. In Switzerland, these technologies are being increasingly adopted, especially by people living with type 1 diabetes, where continuous glucose monitoring (CGM) and automated insulin delivery (AID) systems are considered standards of care. This document provides a comprehensive overview of all diabetes-related technologies currently available in Switzerland. It details their technical specifications, indications for use across diverse populations, compatibility, reimbursement regulations and practical guidance for implementation. Recommendations extend to special populations: children and adolescents, pregnant women, older adults, and people with type 2 diabetes or other specific diabetes types (e.g. maturity-onset diabetes of the young [MODY] or pancreatogenic diabetes). In youth with type 1 diabetes, early adoption of continuous glucose monitoring and automated insulin delivery systems is strongly encouraged and is supported by the Swiss Society of Paediatric Endocrinology and Diabetology. During pregnancy, achieving and maintaining strict glycaemic targets is crucial for reducing pregnancy-related complications. Continuous glucose monitoring and automated insulin delivery improve glycaemic metrics and neonatal outcomes. In older adults, technologies can reduce hypoglycaemia risk and simplify management. For people with type 2 diabetes, continuous glucose monitoring and insulin pumps have shown benefits in glycaemic control, with growing evidence supporting the use of automated insulin delivery systems. The document also highlights the expanding role of telemedicine and remote monitoring. While offering greater accessibility and patient-centred care, these tools raise challenges in terms of digital literacy, interoperability and data protection. Finally, the integration of diabetes and technology into diabetes care requires structured education. Diabetes self-management education and support programmes such as Functional Insulin Therapy (FIT) are essential to help people acquire the knowledge and skills necessary to manage insulin therapy and use diabetes technology effectively and safely. Overall, these recommendations aim to support effective and equitable use of diabetes technology throughout Switzerland and to guide healthcare providers, patients and policymakers towards improving diabetes outcomes.

  • Antibodies Are Predictive for Diagnosis of Celiac Disease in Pediatric Type 1 Diabetes

    by Nadja Zoe Müller, Iulia-Maia Muresan, Arnaud Künzi, Zamir-Zoran Borojevic, Barblin Remund, Marie-Anne Burckhardt, Claudia Boettcher, Christiane Sokollik

    Background: Children and adolescents with type 1 diabetes (T1D) have a higher risk of developing celiac disease (CD) than the general population. However, the main screening antibody, IgA anti-transglutaminase 2 (TGA-IgA), can fluctuate in T1D and there is no threshold for performing diagnostic biopsies. Objectives: The study aims to define an optimal TGA-IgA cutoff for performing diagnostic biopsies for CD confirmation and to assess whether tracking TGA-IgA evolution or adding other antibodies can improve biopsy indications. Methods: Retrospective longitudinal analysis of pediatric T1D individuals diagnosed at 2 centers in Switzerland between 2000 and 2021, from T1D diagnosis to CD diagnosis or the age of 18 years. Results: We included 588 individuals with T1D, comprising 2944 TGA-IgA values. Thirty-four (5.8%) developed CD during follow-up, of whom 50% had CD-associated symptoms at CD diagnosis. Balancing sensitivity and specificity TGA-IgA around 6.1 × upper limit of normal was the best cutoff for performing diagnostic biopsies. The inclusion of IgG antibodies against deamidated gliadin peptides achieved a higher area under the curve of 0.79 (95% CI, 0.6-1) with 80% accuracy compared to each antibody alone. CD diagnosis within 2 years of T1D, representing two thirds of CD, was marked by elevated TGA-IgA at T1D diagnosis. Later CD diagnosis was associated with a more gradual increase of TGA-IgA. Conclusion: Our results suggest an indication for biopsy for CD confirmation at a TGA-IgA cutoff around 6.1 × upper limit of normal. Including IgG antibodies against deamidated gliadin peptides can potentially increase precision. TGA-IgA determination at T1D diagnosis may help to identify individuals at risk of CD early on.


  • Open Access

    Disparities in Diabetes Technology Uptake in Youth and Young Adults With Type 1 Diabetes: A Global Perspective

    by Rebecca Baqiyyah Conway, Janet Snell-Bergeon, Kyoko Honda-Kohmo, Anil Kumar Peddi, Salbiah Binti Isa, Shakira Sulong, Laurien Sibomana, Andrea Gerard Gonzalez, Jooyoun Song, Kate Elizabeth Lomax, et al.

    Globally, nearly 9 million people are living with type 1 diabetes (T1D). Although the incidence of T1D is not affected by socioeconomic status, the development of complications and limited access to modern therapy is overrepresented in vulnerable populations. Diabetes technology, specifically continuous glucose monitoring and automated insulin delivery systems, are considered the gold standard for management of T1D, yet access to these technologies varies widely across countries and regions, and varies widely even within high-income countries. This review focuses on disparities in diabetes technology use among adolescents and young adults with T1D, barriers to access and use, and summarizes common themes emerging across countries and regions. We conducted a survey among medical technology manufacturers and physicians in various countries across diverse geographical regions and performed extensive literature searches. Across all countries and regions, economic barriers stand out as the largest and most common barriers, either preventing market penetrance of technology into a country or limiting its access to the individual with diabetes due to high out of pocket costs. Other common barriers include structural or accessibility barriers, such as stringent eligibility requirements by insurance providers, regardless of whether the insurance was private or government-based, and provider/individual level barriers. Based on the evidence presented, we suggest the need for a joint effort involving governments, private health insurers, technology manufacturers, and healthcare providers to address the global disparities of diabetic technology utilization and ensure equitable access for all individuals living with T1D worldwide.


  • What is the Relationship Between Time in Range, Time in Tight Range, and HbA1c in Youth and Young Adults With Type 1 Diabetes? Results From the German/Austrian/Luxembourgian/Swiss Diabetes Prospective Follow-Up Registry

    by Marie-Anne Burckhardt, Marie Auzanneau, Joachim Rosenbauer, Elisabeth Binder, Jantje Weiskorn, Melanie Hess, Christof Klinkert, Joaquina Mirza, Lara-Sophie Zehnder, Sandra Wenzel, et al.

    Objectives: Time in range (TIR, 70-180 mg/dL) is an established marker of glycemic control. More recently, time in tight range (TTR, 70-140 mg/dL) has been proposed as well. The aim of this study was to examine the relationship between TIR, TTR, and HbA1c in youth and young adults with type 1 diabetes (T1D) in the German/Austrian/Luxembourgian/Swiss Diabetes Prospective Follow-up (DPV) registry. Methods: Data of youth and young adults aged ≤25 years with T1D for >3 months, documented in the DPV registry between 2019 and 2022 were analyzed. The most recent available HbA1c and corresponding continuous glucose monitoring (CGM) profiles in the 12 preceding weeks with at least 80% completeness were included. Associations were investigated using correlation and adjusted regression models. Results: 1901 individuals (median age 14.0 years [IQR 10.4-16.9]) were included in the analysis. TIR and TTR correlated strongly, r = 0.965 (95% CI [0.962, 0.968]), P < .001. TTR estimates predicted from TIR were significantly higher in the group with high coefficient of variation (CV group ≥ 36%), P < .001. Correlations between TIR or TTR and HbA1c were both strong, r = −0.764 (95% CI [−0.782, −0.745]) and r = −0.777 (95% CI [−0.795, −0.759]), both P < .001, with no significant difference ( P = .312) However, adjusted regression models indicated a slightly better fit for the prediction of HbA1c from TIR compared with TTR. Conclusions: Based on large, real-world data from a multinational registry, TIR and TTR correlated strongly, and both showed a good prediction of HbA1c. TTR estimates predicted from TIR were significantly higher in people with high glucose variability (CV).


  • Open Access

    Editorial: Equity in type 1 diabetes technology and beyond: where are we in 2022?

    by Marie-Anne Burckhardt, Ananta Addala, Martin de Bock

    Equity in type 1 diabetes technology and beyond: where are we in 2022? The uptake of diabetes technology, such as continuous glucose monitoring (CGM), insulin pumps and automated insulin delivery, is rapidly increasing in people with type 1 diabetes (T1D), particularly in young people with T1D. Diabetes technology has the potential to be a game-changer, offering improved glycemic control and better psychosocial outcomes. However, it is crucial to acknowledge the existing disparities that hinder equitable access to these advancements. Diabetes technology uptake varies greatly by country, socioeconomic status, race, ethnicity, insurance coverage, and a myriad of social determinants of health (1-4). Inequity in access to technology is one of the key divers of disparities and may become an even more pronounced driver of inequities as the diabetes technology is evolving (5). It has been shown that diabetes technology use is lowest and HbA1c is highest in those from the low socioeconomic status groups (4). This Research Topic encloses high-quality manuscripts on the current topic of equity in T1D technology. One of the major barriers to access to diabetes technology use is payer coverage (6). Lomax et al. compared two different funding models for T1D technology in Australia evaluating differences in technology use across socioeconomic groups. Nationally subsidized CGM use showed similar use across all groups except for the most disadvantaged group who had lower use. Current user pays model implemented for pump use in Australia revealed a pattern of increasing pump use with higher socioeconomic status group, with the lowest pump use in socioeconomically most disadvantaged people living in Australia. To complement the user pays model in Australia and provide access to insulin pump therapy to people who do not have private health insurance to cover insulin pump therapy, alternative pathways such as government or hospital funded programs to access this technology are in place. Fu et al. investigated a sample of children who accessed insulin pump therapy through such subsidization program. These children were able to maintain healthier glycemia for two years. Families favored pumps as a management option. However, financial limitations persisted as a significant barrier to continue pump Frontiers in Endocrinology frontiersin.org 01


  • Open Access

    Following in Banting’s footsteps or straying from the path? Observations from contemporary diabetes innovation

    by Connor Leadley, Ananta Addala, Juliet Berkeley, Hamish Crocket, Elizabeth A. Davis, Niranjala Hewapathirana, Sufyan Hussain, Rayhan Lal, Kate Lomax, Thomas Wilkinson, et al.

    While advancements in the treatment of diabetes continue to rapidly evolve, many of the newer technologies have financial barriers to care, opposing the egalitarian ethos of Banting who sold his patent on insulin for a nominal cost to allow it to be made widely available. Inequity in access to new therapies drives disparity in diabetes burden with potential for these gaps to widen in the future. The 2023 International Conference on Advanced Technologies and Treatments of Diabetes (ATTD) presented ground-breaking and current research in diabetes technology. Oral presentations of the ATTD conference 2023 were analyzed to describe what percentage of speakers discussed equity in their talks. Overall, less than a quarter of presenters discussed equity, though there was regional variation. To ensure that diabetes technologies reduce disparity and improve outcomes, we encourage future speakers at diabetes (technology) conferences to consider equity of diabetes care and incorporate this into their presentations.